Psoriasis and the life cycle of persistent life effects.
Garshick, Marisa Kardos, and Alexa Boer Kimball. 2015. “Psoriasis and the Life Cycle of Persistent Life Effects.”. Dermatologic Clinics 33 (1): 25-39.
Search
Search results
410 results found
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).
Kimball, A B, C Leonardi, M Stahle, W Gulliver, M Chevrier, S Fakharzadeh, K Goyal, et al. 2014. “Demography, Baseline Disease Characteristics and Treatment History of Patients With Psoriasis Enrolled in a Multicentre, Prospective, Disease-Based Registry (PSOLAR).”. The British Journal of Dermatology 171 (1): 137-47.
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
Mattei, P L, K C Corey, and A B Kimball. 2014. “Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The Correlation Between Disease Severity and Psychological Burden in Patients Treated With Biological Therapies.”. Journal of the European Academy of Dermatology and Venereology : JEADV 28 (3): 333-7.
Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09.
Kimball, A B, J Schenfeld, N A Accortt, M S Anthony, K J Rothman, and D Pariser. 2014. “Incidence Rates of Malignancies and Hospitalized Infectious Events in Patients With Psoriasis With or Without Treatment and a General Population in the U.S.A.: 2005-09.”. The British Journal of Dermatology 170 (2): 366-73.
Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants.
Lima, X T, R Minnillo, J M Spencer, and A B Kimball. 2013. “Psoriasis Prevalence Among the 2009 AAD National Melanoma/Skin Cancer Screening Program Participants.”. Journal of the European Academy of Dermatology and Venereology : JEADV 27 (6): 680-5.
Cumulative life course impairment: evidence for psoriasis.
Mattei, Peter L, Kristen C Corey, and Alexa B Kimball. 2013. “Cumulative Life Course Impairment: Evidence for Psoriasis.”. Current Problems in Dermatology 44: 82-90.
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Strober, Bruce, Melinda Gooderham, Elke M G J de Jong, Alexa B Kimball, Richard G Langley, Nikita Lakdawala, Kavitha Goyal, et al. 2018. “Depressive Symptoms, Depression, and the Effect of Biologic Therapy Among Patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. Journal of the American Academy of Dermatology 78 (1): 70-80.
Psoriasis and latitude: Analytic approaches and future data needs.
Hartman, Rebecca I, and Alexa B Kimball. 2017. “Psoriasis and Latitude: Analytic Approaches and Future Data Needs.”. Journal of the American Academy of Dermatology 77 (2): e59.
Psoriasis - The Life Course Approach.
Linder, Michael Dennis, Stefano Piaserico, Matthias Augustin, Anna Belloni Fortina, Arnon D Cohen, Uwe Gieler, Gregor B E Jemec, et al. 2016. “Psoriasis - The Life Course Approach.”. Acta Dermato-Venereologica 96 (217): 102-8.
Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
Kimball, A B, J Schenfeld, N A Accortt, M S Anthony, K J Rothman, and D Pariser. 2015. “Cohort Study of Malignancies and Hospitalized Infectious Events in Treated and Untreated Patients With Psoriasis and a General Population in the United States.”. The British Journal of Dermatology 173 (5): 1183-90.